Johnson & Johnson‘s (JNJ +0.96%) stock price is up more than 7% since the first trading day of November. What’s going on with this healthcare giant?
Well, J&J posted strong third-quarter results in mid-October that beat Wall Street’s estimates. Sales rose nearly 7% over the same quarter last year, to $24 billion, slightly higher than Wall Street expected. And adjusted earnings per share were up 15.7% to $2.80, three cents higher than the consensus estimate. The company also raised full 2025 guidance on revenue growth slightly to 5.7% over 2024 — always a good sign of rising management optimism.
And J&J announced it plans to spin off its slow-growing…
